ABO-Targeted Probiotic Compositions for GI Colonization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current probiotic supplements are ineffective in promoting desired health effects for every individual due to a lack of personalization, as they do not account for variations in ABO blood group-specific bacterial adhesion and resistance to gastrointestinal conditions.
Innovation Solution
Development of probiotic bacteria strains with enhanced adhesion to ABO blood group antigens and improved resistance to acid and bile, characterized by specific adhesion and survival properties, allowing for personalized probiotic compositions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If conventional probiotic supplements are used, then they are available for general use, but they are ineffective in promoting desired health effects for every individual due to lack of personalization
Solution Approach 1:
The patent applies local quality by selecting probiotic bacterial strains with specific adhesion properties tailored to match individual ABO blood group antigens. Each strain is characterized by its preferential adhesion to specific blood group antigens (A, B, or O), creating a customized probiotic composition that matches the individual's genetic profile. This localized matching between bacterial strain and host antigen optimizes colonization and health effects for each individual.
Solution Approach 2:
The patent utilizes parameter changes by measuring and selecting bacterial strains based on their adhesion parameters to specific ABO blood group antigens. The selection process involves quantifying adhesion strength to different antigen types and choosing strains with optimal parameters for the individual's blood group. This parameter-based selection enables personalized probiotic compositions that maximize effectiveness for each individual.
2Reliability
If probiotic bacteria are selected for enhanced adhesion to ABO antigens, then colonization in the gastrointestinal tract is improved, but the complexity of strain selection and characterization increases
Solution Approach 1:
The patent replaces complex mechanical or laboratory-based strain selection processes with a standardized antigen-based selection system. By using ABO blood group antigens as selection criteria, the process becomes more systematic and reproducible. The antigen adhesion characteristics provide objective markers that simplify the selection of appropriate bacterial strains for personalized probiotic compositions.
Solution Approach 2:
The patent applies universality by using ABO blood group antigens as a universal selection criterion that applies across all individuals. The same antigen-based selection framework can be used for any individual regardless of their specific blood group, as the system accommodates A, B, or O antigen types. This universal approach simplifies the selection process while maintaining personalized effectiveness.
3Reliability
If probiotic bacteria are selected for improved acid and bile resistance, then survival in the gastrointestinal tract is enhanced, but the difficulty of detecting and measuring these properties increases
Solution Approach 1:
The patent applies self-service by using the probiotic bacteria's own survival and adhesion characteristics as the measurement criteria. The bacteria are selected based on their inherent ability to survive acid and bile conditions and adhere to ABO antigens, which are direct functional measures of their gastrointestinal tract suitability. This self-assessment approach simplifies measurement by using the bacteria's own performance characteristics rather than requiring complex external measurement systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The enhanced adhesion and survival properties of these strains improve colonization in the gastrointestinal tract, blocking pathogenic adhesion, and providing longer-lasting health benefits through tighter host-probiotic interactions and metabolite delivery.
Implementation Method 1
certain bacterial strains showed enhanced in vitro adhesion to one or more of the ABO blood group antigens
Implementation Method 2
Some probiotic bacteria are more resistant to acid and/or bile
Implementation Method 3
Some probiotic bacteria are more resistant to acid and/or bile
Data Source
AI summary
Bacteria and metabolites thereof that are capable of binding to A, B or O blood type antigens or combinations thereof or which are acid or bile tolerant or both, their use in probiotic compositions and food products, and methods for their selection are disclosed. Methods using said bacteria and metabolites for the prevention or treatment of gastrointestinal disorders or both are also disclosed.